Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2007

View Archived Issues

Recent Schering and CV Therapeutics patents cover novel agents for respiratory disorders

Novel antiinflammatory agents disclosed in recent patent literature

Preclinical characterization of SLV-313, a novel D2 receptor antagonist/5-HT1A receptor agonist

Antiparkinsonian effects of S-32504 via D2 receptors are not associated with significant dyskinesia

Akzo Nobel committed to listing of Organon BioSciences

Otsuka Pharmaceutical establishes new company

Zylera launches Relamine for osteoarthritis

Inologic changes name to ISM Therapeutics

Canadian approval for Champix

New phase II trial evaluates intramuscular peramivir in influenza

Phase IIb study begins for ozarelix in BPH

Pivotal study of Cloretazine in elderly AML patients continues enrollment

Viragen outlines progress of key programs

Survivin validated for designing pancreatic cancer vaccine

GEM OS1 Bone Graft shows efficacy in healing distal radius fractures

Tarceva and radiation studied in pediatric tumors

Acusphere reviews year's activities

Targeting kinase shape control pockets enhances selectivity of small-molecule kinase inhibitors

Pfizer's novel HIV protease inhibitor effective against HIV-resistant strains in preclinical studies

Increasing omega-3 fatty acid intake decreases age-related IOP elevation

Novel PPAR alpha agonist profiled at PRD enters the clinic

CE Mark for Aspirair drug powder inhaler

New therapeutic agents for skin disorders disclosed in recent Pfizer and Ligand patents

Bayer to discontinue non-CABG studies of Trasylol

Combinations with AMG-479 cause pancreatic tumor regression in mice

FDA approval for Mesomark mesothelioma test

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...